906100-43-4Relevant academic research and scientific papers
Free-radical anti-Markovnikov hydroalkylation of unactivated alkenes with simple alkanes
Tian, Yunfei,Ling, Anbo,Fang, Ren,Tan, Ren Xiang,Liu, Zhong-Quan
supporting information, p. 3432 - 3435 (2018/08/07)
A Cu(ii)-mediated radical anti-Markovnikov hydroalkylation of unactivated alkenes with simple alkanes via selective C(sp3)-H bond cleavage was achieved. This reaction features high site-selectivity diverse functional group tolerance, and scalability.
BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS
-
Page/Page column 42; 54, (2015/12/11)
The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.
Anti-markovnikov hydroalkylation of allylic amine derivatives via a palladium-catalyzed reductive cross-coupling reaction
Deluca, Ryan J.,Sigman, Matthew S.
supporting information; experimental part, p. 11454 - 11457 (2011/10/02)
Palladium-catalyzed hydroalkylation of allylic amine derivatives by alkylzinc reagents is reported. This reductive cross-coupling reaction yields anti-Markovnikov products using a variety of allylic amine protecting groups. Preliminary mechanistic studies suggest that a reversible β-hydride elimination/hydride insertion process furnishes the primary Pd-alkyl intermediate, which then undergoes transmetalation followed by reductive elimination to form a new sp3-sp3 carbon-carbon bond.
N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands
Wicek, Ma?gorzata,Kottke, Tim,Ligneau, Xavier,Schunack, Walter,Seifert, Roland,Stark, Holger,Handzlik, Jadwiga,Kie?-Kononowicz, Katarzyna
experimental part, p. 2850 - 2858 (2011/06/21)
Previous studies have shown that several imidazole derivatives posses affinity to histamine H3 and H4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H3/H4 receptor subtypes, two series of 3-(1H-imidazol-4-yl)propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H4 receptor co-expressed with Gαi2 and Gβ1γ2 subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H3 receptor with Ki values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl)propyl pent-4-enylcarbamate with the highest affinity (Ki = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the Nτ-methylhistamine levels in mice with an ED 50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H4 receptor affinity (154-1326 nM).
